Reference
FDA. Due to risk of serious liver injury, FDA restricts use of Ocaliva in primary biliary cholangitis (PBC) patients with advanced cirrhosis. Internet Document : 25 May 2021. Available from: URL: https://www.fda.gov/drugs/drug-safety-and-availability/due-risk-serious-liver-injury-fda-restricts-use-ocaliva-primary-biliary-cholangitis-pbc-patients
Rights and permissions
About this article
Cite this article
FDA restricts use of Ocaliva due to serious liver injury. Reactions Weekly 1858, 4 (2021). https://doi.org/10.1007/s40278-021-96722-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-96722-4